# Quad-Agonist GLP Drugs for Polycystic Ovary Syndrome (PCOS)

Canonical source: https://retacompare.com/research/quad-agonist-glp-drugs-for-polycystic-ovary-syndrome-pcos

Therapeutic Applications · 2026-05-02


    Next-generation GLP drugs, particularly quad-agonists, are being investigated for their potential to address the metabolic and reproductive challenges associated with Polycystic Ovary Syndrome (PCOS), following the promising developments of triple agonists like Retatrutide.

The big picture

Polycystic Ovary Syndrome (PCOS) is a complex endocrine disorder affecting a significant percentage of women of reproductive age. Characterized by insulin resistance, obesity, and reproductive dysfunction, PCOS presents a multifaceted challenge for clinicians. Current treatment options primarily focus on managing symptoms rather than addressing the underlying metabolic dysfunctions. The recent advancements in peptide therapeutics, particularly the development of multi-agonist drugs, have opened new avenues for the treatment of PCOS. Following the progress of Retatrutide, a triple agonist targeting GLP-1, GIP, and glucagon receptors, there is growing interest in the potential of quad-agonists that could further enhance metabolic outcomes and reproductive health in PCOS patients.

How it works

Quad-agonists are designed to simultaneously activate multiple receptors involved in metabolic regulation. The rationale for targeting these receptors lies in their roles in appetite regulation, glucose metabolism, and energy expenditure. For instance, GLP-1 agonists have demonstrated efficacy in weight loss and glycemic control, while glucagon receptor activation can promote energy expenditure. The addition of other pathways, such as amylin or additional incretin pathways, may provide synergistic effects. This multi-faceted approach aims to tackle both the metabolic and reproductive aspects of PCOS, addressing insulin resistance and hormonal imbalances more effectively than mono- or dual-agonist therapies.

Key points at a glance

PCOS affects 5-10% of women of reproductive age, leading to various metabolic and reproductive issues.

Current treatments primarily manage symptoms but do not address underlying metabolic dysfunctions.

Retatrutide is a triple agonist in Phase 3 trials, highlighting the potential of multi-receptor approaches.

Quad-agonists may target GLP-1, GIP, glucagon, and additional pathways to improve outcomes.

Novel combinations could enhance weight loss, improve insulin sensitivity, and restore reproductive function.

Research into quad-agonists is still in early stages, with several candidates in preclinical or early clinical phases.

Where this fits in the pipeline

As of now, no quad-agonist therapies have received regulatory approval. However, several candidates are in various stages of development. For example, programs such as HM15275 from Hanmi and others are exploring the potential of quad-agonists to address obesity and metabolic disorders. These candidates are still in preclinical or early clinical stages, and their efficacy in PCOS remains largely theoretical at this point. The potential for these compounds to address both metabolic and reproductive issues in PCOS is currently a subject of ongoing research.

What it could mean for patients

If successful, quad-agonists could represent a significant advancement in the treatment of PCOS, offering a more comprehensive approach than existing therapies. By targeting multiple receptors involved in metabolic regulation, these drugs could improve weight management, enhance insulin sensitivity, and restore hormonal balance, potentially alleviating the symptoms of PCOS. However, the exact clinical impact remains to be established through rigorous clinical trials, and patients should be cautious about the current speculative nature of these therapies.

Open questions and what we don't yet know

Despite the promise of quad-agonists, several questions remain unanswered. The safety and efficacy of these multi-agonist therapies need to be thoroughly evaluated in clinical trials. Additionally, the long-term effects and potential adverse events associated with activating multiple pathways are not yet fully understood. Regulatory pathways for approval of such complex therapies may also pose challenges, as the FDA and other regulatory bodies assess the safety and efficacy of these novel compounds.

Bottom line

Next-generation quad-agonists hold potential for addressing the multifactorial challenges of PCOS, but further research is essential to validate their efficacy and safety.

This article is research-only educational content and is not medical advice. None of the drugs discussed are approved as quad-agonists or penta-agonists at the time of writing.

## Sources